Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin.

Saved in:
Bibliographic Details
Title: Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin.
Authors: Prickett TD; The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Zerlanko B; The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Gartner JJ; The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Parker SCJ; The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Dutton-Regester K; Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Queensland, Australia., Lin JC; Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA., Teer JK; Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Wei X; The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Jiang J; The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Nisc Comparative Sequencing Program; NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Chen G; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Robinson W; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA., Robinson S; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA., Hayward NK; Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Queensland, Australia., Rosenberg SA; The Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Margulies EH; Genome Informatics Section, Genome Technology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Samuels Y; The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: Yardena.samuels@weizmann.ac.il.
Source: The Journal of investigative dermatology [J Invest Dermatol] 2014 Feb; Vol. 134 (2), pp. 452-460. Date of Electronic Publication: 2013 Sep 05.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 0426720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-1747 (Electronic) Linking ISSN: 0022202X NLM ISO Abbreviation: J Invest Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1523-1747
DOI:10.1038/jid.2013.365